EVT-103
| Clinical data | |
|---|---|
| Other names | ENS-103 |
| Routes of administration | By mouth |
| Drug class | NMDA receptor antagonist |
| Identifiers | |
| CAS Number | |
EVT-103, also known as ENS-103, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.[1] It acts as an NMDA receptor subunit 2B (NR2B) antagonist.[1] As of November 2017, no recent reports of development for major depressive disorder have been identified.[1] The drug was developed as a follow-up compound to EVT-101.[2] The chemical structure of EVT-103 has not been released.[2]
See also
[edit]References
[edit]- ^ a b c "EVT 103". AdisInsight. Springer Nature Switzerland AG.
- ^ a b Ruppa KB, King D, Olson RE (2012). "NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C, and GluN2D Subtypes—Recent Results and Developments". Annual Reports in Medicinal Chemistry Volume 47. Vol. 47. pp. 89–103. doi:10.1016/B978-0-12-396492-2.00007-2. ISBN 9780123964922. ISSN 0065-7743.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |